Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
The DOI matches its Crossref record; 130 of the 132 references it cites were found in a registry or an index.
Abstract
This report summarizes recommendations from the ACNP Task Force on the conceptualization of remission and its implications for defining recovery, relapse, recurrence, and response for clinical investigators and practicing clinicians. Given the strong implications of remission for better function and a better prognosis, remission is a valid, clinically relevant end point for both practitioners and investigators. Not all depressed patients, however, will reach remission. Response is a less desirable primary outcome in trials because it depends highly on the initial (often single) baseline measure of symptom severity. It is recommended that remission be ascribed after 3 consecutive weeks during which minimal symptom status (absence of both sadness and reduced interest/pleasure along with the presence of fewer than three of the remaining seven DSM-IV-TR diagnostic criterion symptoms) is maintained. Once achieved, remission can only be lost if followed by a relapse. Recovery is ascribed after at least 4 months following the onset of remission, during which a relapse has not occurred. Recovery, once achieved, can only be lost if followed by a recurrence. Day-to-day functioning and quality of life are important secondary end points, but they were not included in the proposed definitions of response, remission, recovery, relapse, or recurrence. These recommendations suggest that symptom ratings that measure all nine criterion symptom domains to define a major depressive episode are p…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both reports explicitly requested empirical validations of these now widely used consensus-based definitions.”
From Empirical evidence for definitions of episode, remission, recovery, relapse and recurrence in depression: a systematic review (2019) · cites this paper as Rush et al. (2006)
In the citing paper
“Not only were the specific operationalisations of the duration criteria by Frank et al. (1991) and Rush et al. (2006) not empirically supported”
From Empirical evidence for definitions of episode, remission, recovery, relapse and recurrence in depression: a systematic review (2019) · cites this paper as Rush et al. 2006
In the citing paper
“This definition of relapse is the one most commonly used in clinical studies.39”
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
(1992) · PubMed · Cited by 33,716
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 1×
“These reports have relied on a variety of reasonably chosen remission end points at study exit (eg, 17-item Hamilton Rating Scale for Depression p7 or p6 (HRSD17; Hamilton, 1960, 1967) or MontgomeryÄsberg Depression Rating Scale p10 (MADRS; Montgomery and Äsberg, 1979)).”
MethodThe MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
American Psychiatric Association (2000) · doi:10.1176/appi.books.9780890423349 · Cited by 11,069
Cognitive Therapy for Depression: (675542012-001)
(2012) · PsycEXTRA Dataset · doi:10.1037/e675542012-001 · Cited by 9,663
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Beck, A. T., Steer, R. A., & Brown, G. (2011) · PsycTESTS Dataset · doi:10.1037/t00742-000 · Cited by 7,535
Research works printed but not linked: 2
- American Psychiatric Association (2000b). Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 157 (Suppl 4): 1–45.
- Weissman AN (1979). The dysfunctional attitude scale. A validation study. Diss Abst Int 40: 1389B–1390B.
Cited by
Items 101–200 of 697
Möller, H.-J. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802264606 · Cited by 107
“The ACNP Task Force (Rush et al. 2006) recommended that if the HAMD-17 scale was used, a score of 57 or 55 should be used as criteria for remission.”
MethodZhu, F., Tu, H., & Chen, T. (2022) · Nutrients · doi:10.3390/nu14102081 · Cited by 140
Turkoz, I., Alphs, L., Singh, J., Jamieson, C., Daly, E., Shawi, M., Sheehan, J. J., Trivedi, M. H., & Rush, A. J. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13260 · Cited by 104
Self-citationBalestri, M., Calati, R., Souery, D., Kautzky, A., Kasper, S., Montgomery, S., Zohar, J., Mendlewicz, J., & Serretti, A. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.09.033 · Cited by 102
“We should finally consider that traditional outcomes in clinical studies on MDD mainly focused on symptomatic improvement or response, rather than on full remission, failing to emphasize the substantial impact of residual symptoms on psychosocial dysfunction and poor prognosis (Rush et al., 2006).”
BackgroundBennabi, D., Charpeaud, T., Yrondi, A., Genty, J.-B., Destouches, S., Lancrenon, S., Alaïli, N., Bellivier, F., Bougerol, T., Camus, V., et al. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2237-x · Cited by 100
Berlim, M. T., Fleck, M. P., & Turecki, G. (2008) · Annals of Medicine · doi:10.1080/07853890701769728 · Cited by 100
“Most experts nowadays agree that what constitutes inadequate response to treatment of depression is the failure to achieve remission and not the failure to observe response (15,21).”
BackgroundSartorius, N., Baghai, T. C., Baldwin, D. S., Barrett, B., Brand, U., Fleischhacker, W., Goodwin, G., Grunze, H., Knapp, M., Leonard, B. E., et al. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008255 · Cited by 98
Self-citationRybak, Y. E., Lai, K. S. P., Ramasubbu, R., Vila‐Rodriguez, F., Blumberger, D. M., Chan, P., Delva, N., Giacobbe, P., Gosselin, C., Kennedy, S. H., et al. (2021) · Depression and Anxiety · doi:10.1002/da.23135 · Cited by 97
Vázquez, G. H., Bahji, A., Undurraga, J., Tondo, L., & Baldessarini, R. J. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211013579 · Cited by 95
MahmoudianDehkordi, S., Ahmed, A. T., Bhattacharyya, S., Han, X., Baillie, R. A., Arnold, M., Skime, M. K., John-Williams, L. S., Moseley, M. A., Thompson, J. W., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-020-01097-6 · Cited by 95
Self-citationBareš, M., Brunovský, M., Novák, T., Kopeček, M., Stopková, P., Šóš, P., Krajča, V., & Höschl, C. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.03.007 · Cited by 100
Bobo, W. V., Angleró, G. C., Jenkins, G., Hall‐Flavin, D. K., Weinshilboum, R., & Biernacka, J. M. (2016) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2526 · Cited by 92
“To improve the clinical translation of changes in depression rating scale scores, consensus definitions of response (a clinically significant degree of depressive symptom improvement after treatment initiation) and remission (the virtual absence of depressive symptoms) have been developed (Rush et al., 2006).”
BackgroundDunn, B. D., German, R. E., Khazanov, G., Xu, C., Hollon, S. D., & DeRubeis, R. J. (2020) · Clinical Psychological Science · doi:10.1177/2167702619863427 · Cited by 92
Improving Prescription Drug Warnings to Promote Patient Comprehension
Wolf, M. S., Davis, T. C., Bass, P. F., Curtis, L. M., Lindquist, L. A., Webb, J. A., Bocchini, M. V., Bailey, S. C., & Parker, R. M. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.454 · Cited by 103
Leucht, S., Fennema, H., Engel, R. R., Kaspers–Janssen, M., Lepping, P., & Szegedi, A. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.12.041 · Cited by 96
Rajpurkar, P., Yang, J., Dass, N., Vale, V., Keller, A. S., Irvin, J., Taylor, Z., Basu, S., Ng, A., & Williams, L. M. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.6653 · Cited by 88
Long term outcome of thermal anterior capsulotomy for chronic, treatment refractory depression
Christmas, D., Eljamel, M. S., Butler, S., Hazari, H., MacVicar, R., Steele, J. D., Livingstone, A., & Matthews, K. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.217901 · Cited by 88
“Information regarding the number of previous illness episodes and the duration of inter-illness episode recovery was extracted from detailed case note review to identify the course of individual episodes according to the ACNP Task Force definitions.(19)”
MethodJarrett, R. B., Minhajuddin, A., Gershenfeld, H., Friedman, E. S., & Thase, M. E. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1969 · Cited by 87
Self-citationKluczniok, D., Boedeker, K., Fuchs, A., Hindi Attar, C., Fydrich, T., Fuehrer, D., Dittrich, K., Reck, C., Winter, S., Heinz, A., et al. (2016) · Depression and Anxiety · doi:10.1002/da.22462 · Cited by 87
Clinical research challenges posed by difficult-to-treat depression.
Rush, A. J., Sackeim, H. A., Conway, C. R., Bunker, M. T., Hollon, S. D., Demyttenaere, K., Young, A. H., Aaronson, S. T., Dibué, M., Thase, M. E., et al. (2022) · Psychological Medicine · doi:10.1017/s0033291721004943 · Cited by 89
“Indeed, our understanding of the nat-ural history of mood disorders, the phases of illness, and the phases of treatment (e.g. continuation or maintenance regimens) may not readily apply to DTD (Frank et al., 1991; Rush et al., 2006a).”
InfluentialSelf-citationDefining Success in Measurement-Based Care for Depression: A Comparison of Common Metrics
Coley, R. Y., Boggs, J. M., Beck, A., Hartzler, A. L., & Simon, G. E. (2020) · Psychiatric Services · doi:10.1176/appi.ps.201900295 · Cited by 87
Major depressive disorder: mechanism-based prescribing for personalized medicine
Lapolla, T., Saltiel, P., & Silvershein, D. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s73261 · Cited by 86
Hiller, W., Schindler, A. C., & Lambert, M. J. (2012) · Psychotherapy Research · doi:10.1080/10503307.2011.616237 · Cited by 82
“In the case of depressive disorders, there seems to be widespread international agreement that response requires ] 50% reduction of baseline severity when evaluating the effects of antidepressant treatments (Bandelow, Baldwin, Dolberg, Andersen, & Stein, 2006; Frank et al., 1991; Lecrubier, 2002; Nierenberg & DeCecco,…”
BackgroundMethodTiger, M., Veldman, E. R., Ekman, C.-J., Halldin, C., Svenningsson, P., & Lundberg, J. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0844-4 · Cited by 81
Cohen, S. E., Zantvoord, J. B., Wezenberg, B. N., Bockting, C., & van Wingen, G. A. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01286-x · Cited by 93
Folate and Unipolar Depression
Morris, D. W., Trivedi, M. H., & Rush, A. J. (2008) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2007.0663 · Cited by 80
Self-citationPharmacotherapy of Mood Disorders
Thase, M. E., & Denko, T. (2008) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.2.022305.095301 · Cited by 79
Self-citationThe effect of treatment as usual on major depressive disorder: A meta-analysis
Kolovos, S., van Tulder, M. W., Cuijpers, P., Prigent, A., Chevreul, K., Riper, H., & Bosmans, J. E. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.12.013 · Cited by 79
“…response to treatment (reported as response hereafter) was defined as improvement in depressive symptomatology based on an at least 50% reduction on depressive symptom severity score from baseline to the follow-up measurement (Frank et al., 1991; Jacobson and Truax, 1991b; Rush et al., 2006).”
BackgroundMethodInfluentialMetabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients
Bhattacharyya, S., Ahmed, A. T., Arnold, M., Liu, D., Luo, C., Zhu, H., Mahmoudiandehkordi, S., Neavin, D., Louie, G., Dunlop, B. W., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0507-5 · Cited by 77
Self-citationCooper-Kazaz, R., & Lerer, B. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008206 · Cited by 78
Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: A critical review
Pompili, M., Serafini, G., Innamorati, M., Venturini, P., Fusar-Poli, P., Sher, L., Amore, M., & Girardi, P. (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.765593 · Cited by 78
“The goal of antidepressant treatment in major depressive disorders is to reach full remission of depressive symptoms as well as return to premorbid functioning (Rush et al. 2006).”
BackgroundIniesta, R., Hodgson, K., Stahl, D., Malki, K., Maier, W., Rietschel, M., Mors, O., Hauser, J., Henigsberg, N., Dernovsek, M. Z., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23584-z · Cited by 78
Improving Depression Outcome by Patient-Centered Medical Management
Rush, A. J., & Thase, M. E. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18040398 · Cited by 76
Self-citationWhat predicts attrition in second step medication treatments for depression?: a STAR*D Report
Warden, D., Rush, A. J., Wisniewski, S. R., Lesser, I. M., Kornstein, S. G., Balasubramani, G. K., Thase, M. E., Preskorn, S. H., Nierenberg, A. A., Young, E. A., et al. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009073 · Cited by 77
“…Portions of this paper were presented in poster form at the International Society for Affective Disorders (ISAD), 4th Biennial Conference, Capetown, South Africa, March 2008. symptoms) and remission is associated with improved functioning andprognosis (Hirschfeld et al., 2002;Rush et al., 2006b).”
InfluentialSelf-citationNatural course of cannabis use disorders
Farmer, R. F., Kosty, D. B., Seeley, J. R., Duncan, S. C., Lynskey, M. T., Rohde, P., Klein, D. N., & Lewinsohn, P. M. (2014) · Psychological Medicine · doi:10.1017/s003329171400107x · Cited by 85
IsHak, W. W., Bonifay, W., Collison, K., Reid, M., Youssef, H., Parisi, T., Cohen, R. M., & Cai, L. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.08.081 · Cited by 76
Schmid, M., & Hammar, Å. (2013) · Frontiers in Psychology · doi:10.3389/fpsyg.2013.00633 · Cited by 73
“The definition of a relapse and remission was based on suggested operational criteria for outcomes in depression designed by Frank et al. (1991) and Rush et al. (2006).”
MethodHeerlein, K., Perugi, G., Otte, C., Frodl, T., Degraeve, G., Hagedoorn, W., Oliveira-Maia, A. J., Pérez, V., Rathod, S., Rosso, G., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.03.073 · Cited by 89
“Others have also acknowledged that failure to achieve full remission is associated with an increased risk of relapse and recurrent episodes, as well as the personal and societal burden resulting from residual symptoms (Mendlewicz, 2008; Rush et al., 2006a).”
Lamers, F., Jonkers, C. C. M., Bosma, H., Kempen, G. I. J. M., Meijer, J. A. M. J., Penninx, B. W. J. H., Knottnerus, J. A., & van Eijk, J. T. M. (2010) · Psychotherapy and Psychosomatics · doi:10.1159/000313690 · Cited by 75
When Discontinuing SSRI Antidepressants Is a Challenge: Management Tips
Jha, M. K., Rush, A. J., & Trivedi, M. H. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18060692 · Cited by 73
Self-citationTsai, S., Gau, Y. A., Hong, C., Liou, Y., Yu, Y. W. ‐., & Chen, T. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.04.017 · Cited by 75
“Compared with the traditional method, measuring the intra-individual monthly change in HAM-D21 scores could better aid in the monitoring of changes within a subject, with initial disease severity fixed (Rush et al., 2006).”
MethodStrategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms
Kurian, B. T., Greer, T. L., & Trivedi, M. H. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.53 · Cited by 73
Self-citationPioglitazone could induce remission in major depression: a meta-analysis
Colle, R., de Larminat, D., Rotenberg, S., Hozer, F., Hardy, P., Verstuyft, C., Fève, B., & Corruble, E. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s121149 · Cited by 73
Predicting relapse or recurrence of depression: systematic review of prognostic models
Moriarty, A. S., Meader, N., Snell, K. I. E., Riley, R. D., Paton, L. W., Dawson, S., Hendon, J., Chew-Graham, C. A., Gilbody, S., Churchill, R., et al. (2022) · The British Journal of Psychiatry · doi:10.1192/bjp.2021.218 · Cited by 71
Edwards, S., Hamilton, V, Nherera, L., & Trevor, N. (2013) · Health Technology Assessment · doi:10.3310/hta17540 · Cited by 71
Kantrowitz, J., Citrome, L., & Javitt, D. (2009) · CNS Drugs · doi:10.2165/00023210-200923080-00005 · Cited by 72
What Are the Implications of the STAR*D Trial for Primary Care?: A Review and Synthesis
Huynh, N. N., & McIntyre, R. S. (2008) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.v10n0201 · Cited by 72
Rollman, B. L., Belnap, B. H., LeMenager, M. S., Mazumdar, S., Schulberg, H. C., & Reynolds, C. F. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181970c1c · Cited by 72
Chen, J.-J., Liu, Z., Zhu, D., Li, Q., Zhang, H., Huang, H., Wei, Y., Mu, J., Yang, D., & Xie, P. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.05.010 · Cited by 71
“than response rate (Keller, 2004; Rush et al., 2006).”
BackgroundA systematic review of long-term studies of drug treated and non-drug treated depression
Hughes, S., & Cohen, D. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.01.027 · Cited by 71
Berlim, M. T., Broadbent, H. J., & Van den Eynde, F. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001691 · Cited by 71
“o50% reduction in post-treatment depressive symptoms (Rush et al., 2006) ; data derived from a previous metaanalysis (M.”
MethodTiger, M., Rück, C., Forsberg, A., Varrone, A., Lindefors, N., Halldin, C., Farde, L., & Lundberg, J. (2014) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2014.05.011 · Cited by 70
“Remission was defined as MADRS score o10 (Rush et al., 2006).”
BackgroundCalabrese, J. R., Fava, M., Garibaldi, G. M., Grunze, H., Krystal, A. D., LAUGHREN, T. P., Macfadden, W., Marin, R. S., Nierenberg, A. A., & Tohen, M. F. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.06.056 · Cited by 79
Self-citationMüller, H., Moeller, S., Lücke, C., Lam, A. P., Braun, N., & Philipsen, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00239 · Cited by 81
“This subtype of MDD is classified as therapy-resistant depression (TRD) (Rush et al., 2006a,b;Mojtabai, 2017), which is defined by a lack of response or failure to fully respond or achieve remission after trials of at least two proven antidepressants with adequate dosing and duration (Bschor, 2010;…”
BackgroundBjølseth, T. M., Engedal, K., Benth, J. Š., Dybedal, G. S., Gaarden, T. L., & Tanum, L. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.12.054 · Cited by 68
Kopell, B. H., Halverson, J., Butson, C. R., Dickinson, M., Bobholz, J., Harsch, H., Rainey, C., Kondziolka, D., Howland, R., Eskandar, E., et al. (2011) · Neurosurgery · doi:10.1227/neu.0b013e318229cfcd · Cited by 68
Rodgers, M., Asaria, M., Walker, S., McMillan, D., Lucock, M., Harden, M., Palmer, S., & Eastwood, A. (2012) · Health Technology Assessment · doi:10.3310/hta16280 · Cited by 68
The Impact of Residual Symptoms in Major Depression
Israel, J. A. (2010) · Pharmaceuticals · doi:10.3390/ph3082426 · Cited by 67
“The actual cut-off score between response and remission is somewhat arbitrary [9], and depressed patients themselves may consider symptom resolution a less important indicator of remission than features such as optimism and self-confidence [10].”
BackgroundFirst‑line pharmacotherapies for depression – what is the best choice?
Koenig, A. M., & Thase, M. E. (2009) · Polish Archives of Internal Medicine · doi:10.20452/pamw.743 · Cited by 67
Self-citationPrevention of depression: The state of the science at the beginning of the 21st Century
Barrera, A. Z., Torres, L. D., & Muñoz, R. F. (2007) · International Review of Psychiatry · doi:10.1080/09540260701797894 · Cited by 65
“…standard two-month threshold for operational definitions of recovery (Frank et al., 1991b; Rush et al., 2006), proposed thresholds of four months (Rush et al., 2006), and an empirical study using a six-month threshold (Riso et al., 1997), individuals who have remained episode free beyond one…”
BackgroundInfluentialSeidman, S. N., Orr, G., Raviv, G., Levi, R., Roose, S. P., Kravitz, E., Amiaz, R., & Weiser, M. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181a39137 · Cited by 65
“Because there is no standard criteria used to define DD response and remission, we chose to use criteria typically used for mild, chronic MDD(34) and supported by recent analyses and expert opinion.(35,36) On the basis of this clinical consensus, we used a CGI improvement score of 1 or 2 (much or very much improved, r…”
MethodRush, A. J., Wisniewski, S. R., Zisook, S., Fava, M., Sung, S. C., Haley, C. L., Chan, H. N., Gilmer, W. S., Warden, D., Nierenberg, A. A., et al. (2012) · Psychological Medicine · doi:10.1017/s0033291711002170 · Cited by 65
“1 (5.9) 0.0415 QIDS-SR16 change (”
BackgroundMethodInfluentialSelf-citationProof of concept: Partner-Assisted Interpersonal Psychotherapy for perinatal depression
Brandon, A. R., Ceccotti, N., Hynan, L. S., Shivakumar, G., Johnson, N., & Jarrett, R. B. (2012) · Archives of Women's Mental Health · doi:10.1007/s00737-012-0311-1 · Cited by 65
“Therefore, the scores for inclusion in the sample (16 versus the common threshold of 14) and to assume response (9 versus the common threshold of 6) were similarly elevated in an effort to prevent false diagnosis and missed response (Spinelli 1997; Rush et al. 2006).”
ResultBareš, M., Kopeček, M., Novák, T., Stopková, P., Šóš, P., Kožený, J., Brunovský, M., & Höschl, C. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.01.032 · Cited by 68
Recent Advances in Non-invasive Brain Stimulation for Major Depressive Disorder
Liu, S., Sheng, J., Li, B., & Zhang, X. (2017) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2017.00526 · Cited by 74
“Currently, approximately 1/3 of MDD patients globally exhibit treatment-resistant depression, because of invalid or ineffective antidepressant treatment (Rush et al., 2006).”
BackgroundZibman, S., Pell, G. S., Barnea-Ygael, N., Roth, Y., & Zangen, A. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.06.009 · Cited by 63
Paterniti, S., Sterner, I., Caldwell, C., & Bisserbe, J.-C. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1270-x · Cited by 63
Rush, A. J., South, C. C., Jain, S. B., Agha, R. S., Zhang, M., Shrestha, S., Khan, Z., Hassan, M., & Trivedi, M. H. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s305331 · Cited by 66
“For substantial changes, the values were 4.5 (95% CI [4.21, 4.69]), 6.4 (95% CI [6.08, 6.79]), and 5.6 (95% CI [5.27, 5.86]) for the respective anchors.”
InfluentialSelf-citationUsing Electroencephalography for Treatment Guidance in Major Depressive Disorder
Stade, E. C., & Iosifescu, D. V. (2016) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2016.06.002 · Cited by 71
Kaufling, J. (2019) · Cell and Tissue Research · doi:10.1007/s00441-019-03007-9 · Cited by 63
Reins, J. A., Boß, L., Lehr, D., Berking, M., & Ebert, D. D. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.12.065 · Cited by 61
A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression
Howland, R. H. (2011) · Drug Safety · doi:10.2165/11593960-000000000-00000 · Cited by 67
Improving outcome for mental disorders by enhancing memory for treatment
Harvey, A. G., Lee, J., Smith, R. L., Gumport, N. B., Hollon, S. D., Rabe-Hesketh, S., Hein, K., Dolsen, E. A., Haman, K. L., Kanady, J. C., et al. (2016) · Behaviour Research and Therapy · doi:10.1016/j.brat.2016.03.007 · Cited by 60
“The mood outcomes included change in the severity of depression symptoms, the odds of meeting criteria for American College of Neuropsychopharmacology (ACNP) criteria (Rush et al., 2006) defined ‘response’ and ‘remission’ and the proportion of participants who met diagnostic criteria for MDD.”
Yang, H., Gao, S., Li, J., Yu, H., Xu, J., Lin, C., Yang, H., Teng, C., Ma, H., & Zhang, N. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.915689 · Cited by 82
Clinical Implications of the STAR*D Trial
Rush, A. J., & Jain, S. K. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_153 · Cited by 65
Self-citationSequenced Treatment Alternatives to Relieve Depression (STAR*D): Part 1: Study Design
Howland, R. H. (2008) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20080901-06 · Cited by 59
Berlim, M. T., Richard‐Devantoy, S., dos Santos, N. R., & Turecki, G. (2020) · Psychological Medicine · doi:10.1017/s0033291720001002 · Cited by 65
Christmas, D., Steele, J. D., Tolomeo, S., Eljamel, M. S., & Matthews, K. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.05.080 · Cited by 57
Wang, M.-Y., Liu, I., Chiu, C.-H., & Tsai, P. (2015) · Quality of Life Research · doi:10.1007/s11136-015-1056-x · Cited by 62
Repetitive Transcranial Magnetic Stimulation in Youth With Treatment Resistant Major Depression
MacMaster, F. P., Croarkin, P. E., Wilkes, T. C., McLellan, Q., Langevin, L. M., Jaworska, N., Swansburg, R. M., Jasaui, Y., Zewdie, E., Ciechanski, P., et al. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00170 · Cited by 56
Guerrieri, G. M., Martinez, P. E., Klug, S. P., Haq, N., Vanderhoof, V. H., Koziol, D. E., Popat, V., Kalantaridou, S., Calis, K. A., Rubinow, D. R., et al. (2014) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000195 · Cited by 58
“HAM-D scale scores are based on a 21-item questionnaire, with scores of 14 or higher being consistent with moderate depression (higher scores are indicative of greater symptom severity).(34) SCID values represent the number of women who met DSM-IV criteria for a current major depressive episode.”
MethodManber, R., Kraemer, H. C., Arnow, B. A., Trivedi, M. H., Rush, A. J., Thase, M. E., Rothbaum, B. O., Klein, D. N., Kocsis, J. H., Gelenberg, A. J., et al. (2008) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.76.3.459 · Cited by 54
Self-citationJha, M. K., Minhajuddin, A., South, C. C., Rush, A. J., & Trivedi, M. H. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18030355 · Cited by 58
Self-citationPredicting treatment outcome in depression: an introduction into current concepts and challenges
Rost, N., Binder, E. B., & Brückl, T. M. (2022) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-022-01418-4 · Cited by 77
Maalouf, F. T., Porta, G., Vitiello, B., Emslie, G. J., Mayes, T. L., Clarke, G., Wagner, K. D., Asarnow, J. R., Spirito, A., Keller, M. B., et al. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.12.021 · Cited by 58
“The adolescent version of the Longitudinal Interval Follow-up Evaluation (A-LIFE) (Keller et al., 1987) administered at weeks 12, 24, 48 and 72, was used to rate the week-by-week severity of depressive disorder for the previous 3-month-period.”
Jha, M. K., Minhajuddin, A., Greer, T. L., Carmody, T., Rush, A. J., & Trivedi, M. H. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16020176 · Cited by 53
Self-citationMischoulon, D., Hylek, L., Yeung, A., Clain, A. J., Baer, L., Cusin, C., Ionescu, D. F., Alpert, J. E., Soskin, D. P., & Fava, M. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.08.029 · Cited by 58
Self-citationLerner, D., Adler, D. A., Rogers, W. H., Chang, H., Greenhill, A., Cymerman, E., & Azocar, F. (2015) · Psychiatric Services · doi:10.1176/appi.ps.201400350 · Cited by 53
“For participants with baseline major depression, the severity change indicated remission (<5), treatment response (50% decrease from baseline and not remitting), no change (±2 points from baseline, not remitting or responding) or worsening depression (>2point increase over baseline) (36).”
BackgroundSadness as an integral part of depression
Mouchet-Mages, S., & Bayle, F. (2008) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2008.10.3/smmages · Cited by 64
“However, these scales would not be sufficient to assess remission, as pointed out by the ACNP task force on response and remission in major depressive disorders.(43) The authors postulate that remission implies that the signs and symptoms of the illness must be absent or close to it, with return to the day-to-day func…”
BackgroundA Computerized Decision Support System for Depression in Primary Care
Kurian, B. T., Trivedi, M. H., Grannemann, B. D., Claassen, C. A., Daly, E., & Sunderajan, P. (2009) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.08m00687 · Cited by 54
Self-citationTowards achieving remission in the treatment of depression
Mendlewicz, J. (2008) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2008.10.4/jmendlewicz · Cited by 52
“The ACNP Task Force also reviewed the literature on potential associated factors which may influence the remission, the time of remission and the stability of the remission.(6) These factors include among others the type of treatment, the dose, the duration of treatment, baseline severity of depressive symptoms, the s…”
BackgroundPharmacoepigenetics of depression: no major influence of MAO-A DNA methylation on treatment response
Domschke, K., Tidow, N., Schwarte, K., Ziegler, C., Lesch, K., Deckert, J., Arolt, V., Zwanzger, P., & Baune, B. T. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1227-x · Cited by 61
Evidence-Based Applications of Combination Psychotherapy and Pharmacotherapy for Depression
Dunlop, B. W. (2016) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20150042 · Cited by 111
Schiele, M. A., Zwanzger, P., Schwarte, K., Arolt, V, Baune, B. T., & Domschke, K. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa081 · Cited by 50
Zimmerman, M., Martinez, J., Attiullah, N., Friedman, M., Toba, C., Boerescu, D. A., & Rahgeb, M. (2012) · Depression and Anxiety · doi:10.1002/da.20870 · Cited by 51
“[17] On the HAM-D, the most widely used outcome measure in depression treatment studies, another consensus conference, nearly 15 years after the first, suggested that an alternative cutoff may be preferable.[18] Few studies have examined the validity of alternative cutoff scores to determine remission.”
BackgroundMendlowitz, A. B., Shanbour, A., Downar, J., Vila-Rodriguez, F., Daskalakis, Z. J., Isaranuwatchai, W., & Blumberger, D. M. (2019) · PLOS ONE · doi:10.1371/journal.pone.0222546 · Cited by 51
Tao, R., Emslie, G., Mayes, T., Nakonezny, P., Kennard, B., & Hughes, C. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318190043e · Cited by 51
“, minimal or no depressive symptoms) is the goal of acute treatment.(1) Previous double-blind placebo-controlled acute pediatric antidepressant trials reveal response rates of 40% to 70%, with remission rates of 30% to 40%.”
BackgroundRomera, I., Pérez, V., Menchón, J. M., Polavieja, P., & Gilaberte, I. (2011) · Psychiatry Research · doi:10.1016/j.psychres.2010.06.023 · Cited by 50
“On this basis, on 2006 the American College of Neuropsychopharmacology (ACNP) recommended both using scores of ≤7 or ≤5 (Rush et al., 2006; Moller, 2008).”
MethodKyle, P. R., Lemming, O. M., Timmerby, N., Søndergaard, S., Andreasson, K., & Bech, P. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000557 · Cited by 50
“We compared the proportion of participants who obtained remission at week 8, using NNT.(8) In the latest revision of the British Association for Psychopharmacology guidelines for treating depressive disorders with antidepressants,(14) an NNT of less than 10 is considered to be of clinical significance, which is also a…”
MethodMadore, M. R., Kozel, F. A., Williams, L. M., Green, L. C., George, M. S., Holtzheimer, P. E., Yesavage, J. A., & Philip, N. S. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.10.025 · Cited by 50
Metadata
- Authors
- Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., Regier, D. A., Rosenbaum, J. F., Ray, O., & Schatzberg, A. F.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Stanford Medicine (US)
- University of Pittsburgh (US)
- Emory University (US)
- University of Arizona (US)
- American Psychiatric Association (US)
- Harvard University (US)
- Vanderbilt University (US)
- Corresponding author
- Rush, A John
- ORCID
- Venue
- Neuropsychopharmacology
- Published
- 2006-06-21
- Volume
- 31
- Issue
- 9
- Pages
- 1841-1853
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2039979496
- Cited by
- 707
- References
- 132
- Citations by year
- 2026: 22 · 2025: 23 · 2024: 29 · 2023: 58 · 2022: 30 · 2021: 47 · 2020: 30 · 2019: 47 · 2018: 35 · 2017: 30 · 2016: 41 · 2015: 33 · 2014: 32 · 2013: 36 · 2012: 35
- FWCI
- 4.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Mental Health Research Topics
- Keywords
- major depressive disorder, remission, response, recovery, relapse, recurrence, end points, symptom rating scales, DSM-IV-TR diagnostic criteria, clinical trial results, quality of life
- MeSH terms
- Clinical Trials as Topic, Major Depressive Disorder, Humans, Recurrence, Research Design
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.